Investing.com - BioLineRx reported on Tuesday fourth quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
BioLineRx announced earnings per share of $-0.25 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.2433 on revenue of $0.00.
BioLineRx shares are up 27.38% from the beginning of the year, still down 24.11% from its 52 week high of $4.23 set on February 8. They are outperforming the Nasdaq which is up 2.88% from the start of the year.
BioLineRx shares lost 6.69% in intra-day trade following the report.
BioLineRx follows other major sector earnings this month
BioLineRx's report follows an earnings beat by Ping An Insurance Company of China on February 3, who reported EPS of $0.6308 on revenue of $26.15B, compared to forecasts EPS of $0.6304 on revenue of $24.08B.
SoftBank Group had beat expectations on February 8 with fourth quarter EPS of $2.97 on revenue of $14.41B, compared to forecast for EPS of $0.0374 on revenue of $12.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar